Neutral
Pfizer's eczema drug shows 61% response rate amid Florida lawsuit
Pfizer's eczema treatment achieved a 61% response rate in recent trials, coinciding with a lawsuit filed by Florida alleging deceptive marketing practices. The stock closed at $27.81 on October 2, 2026, down 1.11% from the previous day.
Key points
- Pfizer's eczema drug demonstrates 61% response rate in trials.
- Florida files lawsuit against Pfizer over alleged deceptive marketing.
- Pfizer's stock closes at $27.81, down 1.11% on October 2, 2026.
Sources
- Pfizer’s Eczema Drug Hit a 61% Response Rate the Day Florida Sued. Here’s What It Means for the StockTIKR · October 3, 2026
- Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoBusiness Wire · October 3, 2026
- Pfizer (PFE) Stock Price, News, Quote & HistoryYahoo Finance · October 3, 2026
- Pfizer (PFE) Hits 52-Week High After Earnings Beat and Depo-Provera SettlementEdgeX · September 1, 2026
AI-generated from public news sources. Not financial advice.
